12.05.2022 - REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first .